Since 2014
The cost-effectiveness of introducing a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in elderly Danes
Nordic Journal of Health Economics
View Archive Info| Field | Value | |
| Title |
The cost-effectiveness of introducing a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in elderly Danes
|
|
| Creator |
Bilde, Lone; KORA- Danish Institute of Local and Regional Government Research (former DSI Danish Institute for Health Services Research)
Nielsen, Thomas T Ronholt, Finn Kruse, Marie |
|
| Subject |
Economics, Health, Medicine
herpes zoster, vaccine, cost-effectiveness, Denmark I1, C8, C1, D6 |
|
| Description |
Herpes Zoster is an unpleasant and painful skin condition associated with a risk of developing post-herpetic neuralgia if the pain persists. Herpes Zoster most often occurs in elderly people. This study examines the cost-effectiveness of introducing a vaccine against Herpes Zoster in the Danish health care sector. The cost-effectiveness is examined in a Markov lifetime model framework and populated with Danish data and results from the international literature. From the base case analysis, with an ICER of DKK 261,372 per QALY gained, it seems that an implementation of a vaccine against HZ in the Danish population aged 65 years or more might be cost-effective within generally accepted incremental cost-effectiveness thresholds. Furthermore, an age-specific analysis showed that although the incidence of herpes zoster generally increases with age, targeting the vaccine at persons aged 50-69 years rather than the persons aged 65 years or more, seems to be a more cost-effective strategy from the societal perspective. However, these results are very sensitive to changes in vaccine price, utility values, discount rates, and especially, to the vaccine duration of protection.Published: Online December 2016. In print December 2017.
|
|
| Publisher |
University of Oslo
|
|
| Contributor |
Danish Institute for Health Services Research
Danish Institute for Local and Regional Government Research (KORA) Herlev Hospital Sanofi Pasteur MSD Denmark |
|
| Date |
2016-12-18
|
|
| Type |
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion Peer-reviewed Article |
|
| Format |
application/pdf
|
|
| Identifier |
https://www.journals.uio.no/index.php/NJHE/article/view/1792
10.5617/njhe.1792 |
|
| Source |
Nordic Journal of Health Economics; Vol 5, No 2 (2017): Nordic Journal of Health Economics; pp. 7-27
1892-9710 1892-9729 |
|
| Language |
eng
|
|
| Relation |
https://www.journals.uio.no/index.php/NJHE/article/view/1792/3558
|
|
| Rights |
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
|
|